(Cervical Cancer) Is Cemiplimab Effective? EMPOWER-Cervical 1 Phase 3 Trial Results

• June 7, 2021
• 2 min read

The EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 Phase 3 clinical trial evaluated cemiplimab (anti-PD-1 antibody) versus investigator's choice of chemotherapy in patients with recurrent cervical cancer who had progressed on prior platinum-based therapy. Results were published in the New England Journal of Medicine.

Trial Design:

Patients with recurrent, metastatic, or persistent cervical cancer who had progressed on prior platinum-containing chemotherapy were randomized to receive either cemiplimab 350 mg IV every 3 weeks or investigator's choice of single-agent chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary endpoint was overall survival (OS).

Results:

• Median OS: Cemiplimab 12.0 months vs. chemotherapy 8.5 months
• Hazard ratio: 0.69 (31% reduction in death risk)
• The OS benefit was observed regardless of PD-L1 expression status

Conclusion: Based on the EMPOWER-Cervical 1 trial results, cemiplimab demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy in patients with recurrent cervical cancer following platinum-based therapy.

Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Please consult your healthcare provider for medical decisions.

Source: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9. N Engl J Med. 2021.

Cervical Cancer | Immunotherapy | Cemiplimab

• Clinical Trial Medications

• Immunotherapy

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4